MERIDIAN, Idaho, March 21 /PRNewswire-FirstCall/ -- RxElite, Inc. (OTC Bulletin Board: RXEI), a developer, manufacturer, and marketer of specialty generic prescription drug products, today announced the signing of a multi-source contract award with Premier, Inc. for the sale of RxElite's anesthetic gas products, Sevoflurane and Isoflurane. RxElite was awarded this multi-source contract listing for all classes of trade and the company's anesthetic gas products are immediately available to all Premier members. Sevoflurane is the most commonly used anesthetic gas in the United States and Isoflurane continues to be widely used in anesthesia practice.
"This contract has delivered significant value to the Premier members that have already implemented it and we look forward to continuing to drive value for all Premier members," stated Jonathan Houssian, CEO of RxElite.
RxElite anesthetic gases are manufactured by Minrad International, Inc., a leader in the innovation of anesthesia. RxElite holds the exclusive distribution rights for Minrad produced anesthetic gases for the human market in the United States.
About RxElite, Inc
RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia and sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs).
About Premier, Inc., 2006 Malcolm Baldrige National Quality Award
recipient -- Serving 1,700 U.S. hospitals and more than 49,000 other
healthcare sites, the Premier healthcare alliance and its members are
transforming healthcare together. Owned by not-for-profit hospitals,
Premier operates one of the leading healthcare purchasing networks and the
nation's most comprehensive repository of hospital clinical and financial
information. A subsidiary operates one of the nation's largest
policy-holder owned, hospital professional liability ri
|SOURCE RxElite, Inc.|
Copyright©2008 PR Newswire.
All rights reserved